NovoCure (NVCR) Financials

$15.83 -0.63 (-3.83%)

As of 04:00 PM Eastern

Annual Income Statements for NovoCure

This table shows NovoCure's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-81	-112	-132	-62	-64	-7.23	20	-58	-93	-207	-169
Consolidated Net Income / (Loss)	-81	-112	-132	-62	-64	-7.23	20	-58	-93	-207	-169
Net Income / (Loss) Continuing Operations	-81	-112	-132	-62	-64	-7.23	20	-58	-93	-207	-169
Total Pre-Tax Income	-80	-107	-121	-48	-46	-8.82	18	-52	-82	-192	-131
Total Operating Income	-80	-104	-115	-39	-34	-0.91	30	-44	-90	-233	-170
Total Gross Profit	5.45	12	37	121	168	263	388	420	423	381	468
Total Revenue	15	33	83	177	248	351	494	535	538	509	605
Operating Revenue	15	33	83	177	248	351	494	535	538	509	605
Total Cost of Revenue	10	21	46	56	80	89	107	115	115	128	137
Operating Cost of Revenue	10	21	40	56	80	89	107	115	115	128	137
Total Operating Expenses	86	116	152	161	202	264	357	464	512	614	639
Selling, General & Admin Expense	24	34	51	59	73	88	107	126	133	164	190
Marketing Expense	21	39	59	64	78	97	118	137	174	227	239
Research & Development Expense	40	44	41	38	51	79	132	201	206	223	210
Total Other Income / (Expense), net	-0.14	-3.15	-6.15	-9.17	-12	-7.91	-12	-7.74	7.68	41	39
Interest & Investment Income	-	-	-	-	-	-	-12	-7.74	7.68	41	39
Income Tax Expense	0.38	4.43	10	13	18	-1.59	-1.71	6.28	11	15	37
Basic Earnings per Share	($6.46)	($3.67)	($1.54)	($0.70)	($0.69)	($0.07)	$0.20	($0.56)	($0.88)	($1.95)	($1.56)
Weighted Average Basic Shares Outstanding	12.49M	30.40M	85.56M	88.55M	91.83M	97.24M	100.93M	103.43M	104.66M	106.39M	107.83M
Diluted Earnings per Share	($6.46)	($3.67)	($1.54)	($0.70)	($0.69)	($0.07)	$0.18	($0.56)	($0.88)	($1.95)	($1.56)
Weighted Average Diluted Shares Outstanding	12.49M	30.40M	85.56M	88.55M	91.83M	97.24M	108.88M	103.43M	104.66M	106.39M	107.83M
Weighted Average Basic & Diluted Shares Outstanding	12.49M	30.40M	85.56M	88.55M	91.83M	97.24M	102.41M	104.42M	105.46M	107.09M	109.92M

This table shows NovoCure's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-27	-37	-53	-57	-49	-47	-39	-33	-31	-66
Consolidated Net Income / (Loss)	-27	-37	-53	-57	-49	-47	-39	-33	-31	-66
Net Income / (Loss) Continuing Operations	-27	-37	-53	-57	-49	-47	-39	-33	-31	-66
Total Pre-Tax Income	-23	-33	-51	-54	-48	-39	-32	-23	-22	-55
Total Operating Income	-25	-43	-60	-63	-58	-52	-42	-34	-32	-63
Total Gross Profit	101	100	93	92	95	101	105	116	120	128
Total Revenue	131	128	122	126	127	134	139	150	155	161
Operating Revenue	131	128	122	126	127	134	139	150	155	161
Total Cost of Revenue	30	29	30	34	32	33	34	35	35	33
Operating Cost of Revenue	30	29	30	34	32	33	34	35	35	33
Total Operating Expenses	126	143	153	155	153	153	146	149	152	191
Selling, General & Admin Expense	33	38	42	41	42	39	40	38	40	72
Marketing Expense	41	50	51	58	58	59	55	57	60	67
Research & Development Expense	52	55	60	55	54	54	52	55	52	51
Total Other Income / (Expense), net	1.19	10	9.17	8.76	10	13	9.88	11	11	8.10
Interest & Investment Income	-	-	9.17	8.76	10	13	9.88	11	11	8.10
Income Tax Expense	3.16	4.75	1.98	3.51	1.26	8.55	7.12	11	8.99	11
Basic Earnings per Share	($0.25)	($0.36)	($0.50)	($0.54)	($0.46)	($0.45)	($0.36)	($0.31)	($0.28)	($0.61)
Weighted Average Basic Shares Outstanding	104.88M	104.66M	105.67M	106.29M	106.77M	106.39M	107.27M	107.70M	108.25M	107.83M
Diluted Earnings per Share	($0.25)	($0.36)	($0.50)	($0.54)	($0.46)	($0.45)	($0.36)	($0.31)	($0.28)	($0.61)
Weighted Average Diluted Shares Outstanding	104.88M	104.66M	105.67M	106.29M	106.77M	106.39M	107.27M	107.70M	108.25M	107.83M
Weighted Average Basic & Diluted Shares Outstanding	104.95M	105.46M	106.21M	106.62M	106.86M	107.09M	107.61M	108.22M	108.20M	109.92M

This table details how cash moves in and out of NovoCure's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-118	62	-19	-19	62	37	67	-37	-94	127	-76
Net Cash From Operating Activities	-74	-100	-108	-33	-1.87	27	99	83	31	-73	-26
Net Cash From Continuing Operating Activities	-74	-100	-108	-33	-1.87	27	99	83	31	-73	-26
Net Income / (Loss) Continuing Operations	-81	-112	-132	-62	-64	-7.23	20	-58	-93	-207	-169
Consolidated Net Income / (Loss)	-81	-112	-132	-62	-64	-7.23	20	-58	-93	-207	-169
Depreciation Expense	1.96	3.15	5.65	7.68	9.01	8.46	9.15	10	11	11	11
Amortization Expense	-0.02	0.33	0.16	0.25	1.02	-2.18	3.26	3.10	-1.54	-23	-26
Non-Cash Adjustments To Reconcile Net Income	3.46	6.82	28	27	40	52	75	104	107	146	135
Changes in Operating Assets and Liabilities, net	1.04	1.40	-9.68	-6.76	11	-24	-8.52	24	7.03	0.15	22
Net Cash From Investing Activities	-46	-115	13	8.63	-5.49	-52	-473	-145	-140	184	-140
Net Cash From Continuing Investing Activities	-46	-115	13	8.63	-5.49	-52	-473	-145	-140	184	-140
Purchase of Property, Plant & Equipment	-0.85	-4.67	-5.67	-7.37	-6.71	-10	-15	-24	-21	-27	-43
Purchase of Investments	-138	-209	-239	-104	-254	-462	-608	-1,079	-1,298	-1,004	-875
Sale and/or Maturity of Investments	93	104	270	120	255	421	150	958	1,179	1,215	778
Net Cash From Financing Activities	2.15	277	75	5.17	69	62	440	26	15	16	90
Net Cash From Continuing Financing Activities	2.15	277	75	5.17	69	62	440	26	15	16	90
Repayment of Debt	-0.06	-	-	-0.08	-100	-	-150	-0.03	-0.03	-0.01	-13
Issuance of Debt	0.05	23	73	0.02	149	-0.03	558	0.00	0.00	0.00	97
Issuance of Common Equity	2.15	254	0.62	1.54	1.84	2.47	3.37	4.55	5.22	4.42	4.15
Other Financing Activities, net	-	-	1.69	3.69	18	59	28	21	10	11	2.16
Effect of Exchange Rate Changes	-	-	-	-	-	0.03	0.25	-0.19	-0.10	0.13	-0.17
Cash Interest Paid	0.03	1.69	6.60	10	13	14	8.69	0.10	0.04	0.01	7.71
Cash Income Taxes Paid	0.28	1.49	9.45	10	20	11	-3.26	3.11	5.48	14	23

This table details how cash moves in and out of NovoCure's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-124	-128	71	-29	-0.98	86	215	-289	21	-23
Net Cash From Operating Activities	22	-3.71	-17	-23	-19	-15	-32	-1.72	10	-3.45
Net Cash From Continuing Operating Activities	22	-3.71	-17	-23	-19	-15	-32	-1.72	10	-3.45
Net Income / (Loss) Continuing Operations	-27	-37	-53	-57	-49	-47	-39	-33	-31	-66
Consolidated Net Income / (Loss)	-27	-37	-53	-57	-49	-47	-39	-33	-31	-66
Depreciation Expense	2.66	2.70	2.72	2.72	2.80	2.72	2.82	2.86	2.46	3.10
Amortization Expense	0.23	-3.28	-4.06	-5.08	-6.69	-7.26	-5.38	-6.85	-6.74	-6.67
Non-Cash Adjustments To Reconcile Net Income	26	28	54	41	30	21	32	22	37	45
Changes in Operating Assets and Liabilities, net	20	5.71	-16	-3.70	3.56	16	-22	14	8.50	21
Net Cash From Investing Activities	-150	-128	82	-14	17	99	246	-374	10	-22
Net Cash From Continuing Investing Activities	-150	-128	82	-14	17	99	246	-374	10	-22
Purchase of Property, Plant & Equipment	-5.70	-6.43	-6.09	-6.93	-7.25	-6.82	-12	-11	-11	-8.94
Purchase of Investments	-503	-226	-238	-322	-251	-193	0.00	-523	-169	-183
Sale and/or Maturity of Investments	359	105	326	315	276	299	258	160	190	170
Net Cash From Financing Activities	4.20	3.41	5.20	7.50	1.17	1.91	0.21	87	0.10	2.69
Net Cash From Continuing Financing Activities	4.20	3.41	5.20	7.50	1.17	1.91	0.21	87	0.10	2.69
Issuance of Common Equity	-	2.47	0.00	2.88	-	1.53	0.00	2.19	-	1.96
Other Financing Activities, net	4.21	0.95	5.21	4.62	1.17	0.38	0.21	1.12	0.10	0.72
Effect of Exchange Rate Changes	-0.11	0.16	0.04	-0.01	-0.10	0.20	-0.06	-0.08	0.09	-0.13
Cash Interest Paid	0.00	0.04	0.00	-	-	0.01	0.00	1.97	2.96	2.78
Cash Income Taxes Paid	0.91	1.55	1.71	5.83	1.20	4.92	2.91	7.50	6.64	6.41

This table presents NovoCure's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	118	307	282	265	340	479	1,052	1,139	1,192	1,146	1,241
Total Current Assets	112	294	262	245	321	440	999	1,074	1,112	1,034	1,107
Cash & Equivalents	58	119	100	79	141	177	235	209	115	241	164
Restricted Cash	0.06	0.09	0.27	2.13	2.13	2.10	11	0.81	0.51	1.74	2.33
Short-Term Investments	45	150	120	105	105	149	608	729	854	670	796
Accounts Receivable	-	0.00	6.34	30	37	59	97	94	86	61	74
Inventories, net	3.45	14	26	22	23	24	27	24	29	38	35
Other Current Assets	5.71	11	10	8.11	14	29	21	17	26	23	35
Plant, Property, & Equipment, net	3.73	6.55	9.81	9.03	8.44	9.34	11	23	33	51	78
Total Noncurrent Assets	2.31	6.88	10	11	9.98	30	41	43	47	60	57
Other Noncurrent Operating Assets	2.31	6.88	10	11	9.98	30	41	43	47	60	57
Total Liabilities & Shareholders' Equity	118	307	282	265	340	479	1,052	1,139	1,192	1,146	1,241
Total Liabilities	20	57	140	152	228	262	575	729	750	784	881
Total Current Liabilities	18	29	37	50	65	86	114	143	159	179	756
Short-Term Debt	-	-	-	-	-	-	-	-	-	0.00	558
Accounts Payable	18	29	37	50	65	86	54	73	85	94	105
Accrued Expenses	-	-	-	-	-	-	60	70	74	85	93
Total Noncurrent Liabilities	2.33	28	103	102	163	175	462	586	592	605	124
Long-Term Debt	0.00	23	96	97	149	149	430	562	566	569	97
Noncurrent Employee Benefit Liabilities	0.25	2.06	2.59	2.45	2.68	3.75	5.17	4.54	4.40	8.26	6.94
Other Noncurrent Operating Liabilities	2.09	2.74	4.03	1.74	1.09	0.22	0.34	0.17	19	27	20
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	98	251	142	114	112	218	477	410	441	362	360
Total Preferred & Common Equity	98	251	142	114	112	218	477	410	441	362	360
Total Common Equity	98	251	142	114	112	218	477	410	441	362	360
Common Stock	374	640	664	697	757	871	1,111	1,100	1,222	1,353	1,520
Retained Earnings	-277	-388	-520	-582	-644	-651	-631	-686	-778	-986	-1,154
Accumulated Other Comprehensive Income / (Loss)	0.00	-1.51	-1.88	-1.34	-1.40	-2.77	-3.83	-3.17	-2.43	-5.47	-5.50

This table presents NovoCure's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,174	1,174	1,159	1,146	1,121	1,212	1,222
Total Current Assets	1,102	1,089	1,065	1,048	1,003	1,093	1,095
Cash & Equivalents	244	186	157	155	454	165	185
Restricted Cash	0.23	0.68	0.52	1.65	3.60	3.65	3.78
Short-Term Investments	727	772	784	766	416	786	774
Accounts Receivable	88	75	71	65	65	65	67
Inventories, net	27	32	33	37	42	40	39
Other Current Assets	17	-	20	23	21	33	25
Plant, Property, & Equipment, net	30	36	41	46	59	66	73
Total Noncurrent Assets	42	49	52	53	60	53	53
Other Noncurrent Operating Assets	42	49	52	53	60	53	53
Total Liabilities & Shareholders' Equity	1,174	1,174	1,159	1,146	1,121	1,212	1,222
Total Liabilities	729	742	743	753	762	850	861
Total Current Liabilities	141	149	150	157	160	169	735
Short-Term Debt	-	-	-	-	-	-	557
Accounts Payable	77	81	83	80	84	90	91
Accrued Expenses	64	67	68	77	76	79	86
Total Noncurrent Liabilities	588	593	593	595	602	681	126
Long-Term Debt	565	566	567	568	570	653	97
Noncurrent Employee Benefit Liabilities	4.09	5.14	4.84	5.37	6.57	6.02	7.89
Other Noncurrent Operating Liabilities	15	20	20	22	26	22	21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	445	432	416	394	359	362	361
Total Preferred & Common Equity	445	432	416	394	359	362	361
Total Common Equity	445	432	416	394	359	362	361
Common Stock	1,189	1,266	1,307	1,334	1,388	1,423	1,454
Retained Earnings	-741	-832	-889	-938	-1,024	-1,058	-1,088
Accumulated Other Comprehensive Income / (Loss)	-2.31	-2.69	-1.98	-1.99	-4.15	-3.52	-5.38

This table displays calculated financial ratios and metrics derived from NovoCure's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	49.53%	113.60%	150.52%	113.57%	40.13%	41.62%	40.72%	8.23%	0.53%	-5.30%	18.82%
EBITDA Growth	-35.29%	-28.51%	-8.95%	71.33%	24.70%	122.71%	697.23%	-172.37%	-159.63%	-204.58%	24.52%
EBIT Growth	-24.35%	-29.74%	-10.89%	65.90%	14.38%	97.29%	3,426.15%	-245.83%	-101.93%	-160.12%	26.78%
NOPAT Growth	-24.35%	-29.74%	-10.89%	65.90%	14.38%	97.29%	5,299.45%	-193.29%	-101.93%	-160.12%	26.78%
Net Income Growth	-4.28%	-38.30%	-18.16%	53.23%	-3.08%	88.62%	373.97%	-394.58%	-58.58%	-123.75%	18.55%
EPS Growth	4.01%	43.19%	58.04%	54.55%	1.43%	89.86%	357.14%	-411.11%	-57.14%	-121.59%	20.00%
Operating Cash Flow Growth	-40.84%	-34.53%	-7.72%	69.20%	94.37%	1,527.35%	272.46%	-16.53%	-62.80%	-338.20%	64.04%
Free Cash Flow Firm Growth	0.00%	-59.81%	-15.84%	63.87%	66.16%	-246.87%	149.10%	-158.55%	-350.72%	-178.14%	-5.93%
Invested Capital Growth	0.00%	191.83%	323.85%	36.38%	-46.94%	293.41%	25.35%	-29.18%	-22.15%	-48.41%	181.87%
Revenue Q/Q Growth	0.00%	0.00%	27.46%	15.25%	6.90%	9.19%	9.95%	-1.97%	-0.88%	1.06%	4.76%
EBITDA Q/Q Growth	0.00%	0.00%	10.76%	30.58%	-24.23%	244.16%	61.62%	-516.36%	-41.56%	-5.47%	-6.09%
EBIT Q/Q Growth	0.00%	0.00%	9.94%	25.37%	-14.09%	90.61%	64.67%	-401.33%	-27.99%	-3.90%	-7.29%
NOPAT Q/Q Growth	0.00%	0.00%	9.94%	25.37%	-14.09%	90.61%	-27.69%	-401.33%	-27.99%	-3.90%	-7.29%
Net Income Q/Q Growth	0.00%	0.00%	7.55%	15.40%	-7.96%	73.34%	3.43%	-116.31%	-13.28%	-4.96%	-12.58%
EPS Q/Q Growth	0.00%	0.00%	-222.22%	15.66%	-6.15%	75.00%	-10.00%	-100.00%	-14.29%	-4.84%	-11.43%
Operating Cash Flow Q/Q Growth	0.00%	-9.31%	10.33%	24.63%	91.36%	-27.01%	88.39%	-32.07%	-37.04%	-17.37%	29.64%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	20.81%	61.12%	-1,752.54%	3,227.03%	-145.33%	-7.49%	7.00%	-24.02%
Invested Capital Q/Q Growth	0.00%	0.00%	0.43%	1.68%	-60.56%	112.54%	-6.99%	18.26%	-7.04%	-51.12%	3.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	35.21%	37.71%	44.16%	68.59%	67.73%	74.78%	78.46%	78.53%	78.64%	74.81%	77.33%
EBITDA Margin	-504.93%	-303.79%	-132.12%	-17.74%	-9.53%	1.53%	8.66%	-5.79%	-14.96%	-48.10%	-30.55%
Operating Margin	-517.47%	-314.31%	-139.12%	-22.22%	-13.57%	-0.26%	6.15%	-8.29%	-16.64%	-45.72%	-28.17%
EBIT Margin	-517.47%	-314.31%	-139.12%	-22.22%	-13.57%	-0.26%	6.15%	-8.29%	-16.64%	-45.72%	-28.17%
Profit (Net Income) Margin	-520.87%	-337.24%	-159.06%	-34.83%	-25.62%	-2.06%	4.01%	-10.91%	-17.20%	-40.65%	-27.86%
Tax Burden Percent	100.48%	104.14%	108.55%	127.15%	138.35%	81.94%	109.42%	112.05%	113.06%	107.98%	128.56%
Interest Burden Percent	100.18%	103.03%	105.33%	123.31%	136.44%	965.43%	59.54%	117.46%	91.42%	82.34%	76.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-9.42%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-699.47%	-124.73%	-120.92%	-1.92%	55.53%	-54.52%	-149.30%	-585.26%	-329.70%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-671.84%	-92.49%	-78.12%	3.09%	60.21%	-47.45%	-141.52%	-573.48%	-314.54%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	632.40%	76.54%	64.63%	-2.46%	-49.82%	41.36%	127.57%	533.73%	283.03%
Return on Equity (ROE)	-82.43%	-64.00%	-67.07%	-48.19%	-56.29%	-4.38%	5.71%	-13.16%	-21.73%	-51.52%	-46.67%
Cash Return on Invested Capital (CROIC)	0.00%	-1,861.13%	-823.11%	-155.51%	-59.60%	-120.85%	33.03%	-20.35%	-124.39%	-521.40%	-424.95%
Operating Return on Assets (OROA)	-68.00%	-48.91%	-39.13%	-14.37%	-11.13%	-0.22%	3.97%	-4.05%	-7.68%	-19.92%	-14.29%
Return on Assets (ROA)	-68.45%	-52.48%	-44.74%	-22.53%	-21.01%	-1.77%	2.59%	-5.33%	-7.94%	-17.71%	-14.13%
Return on Common Equity (ROCE)	-82.43%	-64.00%	-67.07%	-48.19%	-56.29%	-4.38%	5.71%	-13.16%	-21.73%	-51.52%	-46.67%
Return on Equity Simple (ROE_SIMPLE)	-82.43%	-44.49%	-92.62%	-54.30%	-56.62%	-3.32%	4.16%	-14.21%	-20.97%	-57.12%	-46.82%
Net Operating Profit after Tax (NOPAT)	-56	-73	-81	-28	-24	-0.64	33	-31	-63	-163	-119
NOPAT Margin	-362.23%	-220.02%	-97.39%	-15.55%	-9.50%	-0.18%	6.73%	-5.80%	-11.65%	-32.00%	-19.72%
Net Nonoperating Expense Percent (NNEP)	-47.87%	-22.22%	-27.63%	-32.24%	-42.81%	-5.00%	-4.69%	-7.07%	-7.78%	-11.77%	-15.16%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-6.23%	-17.50%	-11.75%
Cost of Revenue to Revenue	64.79%	62.29%	55.84%	31.41%	32.27%	25.22%	21.54%	21.47%	21.36%	25.19%	22.67%
SG&A Expenses to Revenue	155.27%	102.35%	61.54%	33.39%	29.61%	25.03%	21.73%	23.57%	24.68%	32.21%	31.37%
R&D to Revenue	260.69%	132.22%	50.03%	21.52%	20.39%	22.49%	26.70%	37.62%	38.32%	43.79%	34.64%
Operating Expenses to Revenue	552.68%	352.02%	183.29%	90.80%	81.31%	75.04%	72.31%	86.82%	95.29%	120.53%	105.50%
Earnings before Interest and Taxes (EBIT)	-80	-104	-115	-39	-34	-0.91	30	-44	-90	-233	-170
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-78	-101	-110	-31	-24	5.37	43	-31	-80	-245	-185
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	7.45	4.79	15.90	27.74	38.29	36.97	18.99	17.45	4.40	8.95
Price to Tangible Book Value (P/TBV)	0.00	7.45	4.79	15.90	27.74	38.29	36.97	18.99	17.45	4.40	8.95
Price to Revenue (P/Rev)	0.00	56.51	8.22	10.20	12.55	23.74	35.63	14.57	14.31	3.13	5.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	889.29	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.11%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	368.43	29.86	67.42	223.11	153.76	258.15	157.45	198.49	66.03	54.60
Enterprise Value to Revenue (EV/Rev)	0.00	49.06	6.73	9.70	12.16	23.27	34.80	13.89	13.56	2.46	4.82
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	1,522.43	401.89	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	565.94	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	517.20	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	307.12	173.53	89.80	236.90	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	869.56	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.09	0.68	0.86	1.33	0.75	0.93	1.40	1.28	1.57	1.82
Long-Term Debt to Equity	0.00	0.09	0.68	0.86	1.33	0.75	0.93	1.40	1.28	1.57	0.27
Financial Leverage	-1.05	-1.00	-0.94	-0.83	-0.83	-0.80	-0.83	-0.87	-0.90	-0.93	-0.90
Leverage Ratio	1.20	1.22	1.50	2.14	2.68	2.48	2.21	2.47	2.74	2.91	3.30
Compound Leverage Factor	1.21	1.26	1.58	2.64	3.66	23.96	1.31	2.90	2.50	2.40	2.54
Debt to Total Capital	0.00%	8.43%	40.34%	46.15%	57.08%	42.89%	48.24%	58.36%	56.18%	61.08%	64.54%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	54.96%
Long-Term Debt to Total Capital	0.00%	8.43%	40.34%	46.15%	57.08%	42.89%	48.24%	58.36%	56.18%	61.08%	9.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	91.57%	59.66%	53.85%	42.92%	57.11%	51.76%	41.64%	43.82%	38.92%	35.46%
Debt to EBITDA	0.00	-0.23	-0.88	-3.10	-6.31	30.46	10.38	-18.57	-7.03	-2.32	-3.54
Net Debt to EBITDA	0.00	2.45	1.13	2.81	4.18	-30.66	-9.57	11.73	5.03	1.40	1.66
Long-Term Debt to EBITDA	0.00	-0.23	-0.88	-3.10	-6.31	30.46	10.38	-18.57	-7.03	-2.32	-0.53
Debt to NOPAT	0.00	-0.32	-1.19	-3.54	-6.33	-255.65	13.35	-18.54	-9.02	-3.49	-5.49
Net Debt to NOPAT	0.00	3.38	1.53	3.20	4.19	257.30	-12.32	11.71	6.45	2.11	2.57
Long-Term Debt to NOPAT	0.00	-0.32	-1.19	-3.54	-6.33	-255.65	13.35	-18.54	-9.02	-3.49	-0.82
Altman Z-Score	0.00	18.11	0.25	5.13	6.87	18.84	19.10	6.89	6.40	0.69	1.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.33	10.27	7.10	4.88	4.98	5.10	8.80	7.53	7.00	5.78	1.46
Quick Ratio	5.81	9.41	6.13	4.24	4.37	4.46	8.27	7.23	6.65	5.43	1.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-51	-82	-95	-34	-12	-40	20	-12	-52	-145	-154
Operating Cash Flow to CapEx	-8,744.88%	-2,140.22%	-1,896.56%	-449.82%	-27.79%	253.89%	662.40%	342.39%	144.15%	-270.68%	-61.53%
Free Cash Flow to Firm to Interest Expense	-356.33	-26.02	-15.45	-3.74	-0.95	-5.09	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-515.58	-31.70	-17.50	-3.61	-0.15	3.37	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-521.48	-33.18	-18.43	-4.42	-0.70	2.04	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.16	0.28	0.65	0.82	0.86	0.65	0.49	0.46	0.44	0.51
Accounts Receivable Turnover	0.00	0.00	0.00	9.86	7.51	7.37	6.36	5.62	5.98	6.91	8.94
Inventory Turnover	2.91	2.42	2.36	2.34	3.59	3.83	4.17	4.43	4.27	3.80	3.75
Fixed Asset Turnover	4.15	6.43	10.13	18.79	28.39	39.51	47.68	31.39	19.43	12.10	9.37
Accounts Payable Turnover	0.57	0.89	1.41	1.28	1.40	1.17	1.52	1.82	1.46	1.43	1.38
Days Sales Outstanding (DSO)	0.00	0.00	0.00	37.02	48.62	49.55	57.43	64.90	61.02	52.84	40.84
Days Inventory Outstanding (DIO)	125.33	150.89	154.35	156.13	101.64	95.27	87.60	82.37	85.48	96.07	97.43
Days Payable Outstanding (DPO)	642.61	409.95	258.32	285.79	261.64	310.75	239.83	200.56	250.71	255.49	265.38
Cash Conversion Cycle (CCC)	-517.28	-259.06	-103.97	-92.65	-111.39	-165.93	-94.80	-53.29	-104.21	-106.58	-127.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-4.80	4.41	19	25	14	53	67	47	37	19	53
Invested Capital Turnover	-6.46	-168.81	7.18	8.02	12.73	10.54	8.25	9.40	12.81	18.29	16.72
Increase / (Decrease) in Invested Capital	-4.80	9.20	14	6.79	-12	40	13	-19	-10	-18	34
Enterprise Value (EV)	0.00	1,623	558	1,717	3,015	8,175	17,205	7,431	7,294	1,252	2,918
Market Capitalization	0.00	1,870	681	1,805	3,114	8,340	17,615	7,795	7,698	1,595	3,224
Book Value per Share	$7.84	$3.00	$1.64	$1.27	$1.21	$2.20	$4.68	$3.95	$4.20	$3.39	$3.33
Tangible Book Value per Share	$7.84	$3.00	$1.64	$1.27	$1.21	$2.20	$4.68	$3.95	$4.20	$3.39	$3.33
Total Capital	98	274	239	211	262	381	921	986	1,007	931	1,016
Total Debt	0.00	23	96	97	149	164	444	575	566	569	655
Total Long-Term Debt	0.00	23	96	97	149	164	444	575	566	569	97
Net Debt	-103	-246	-124	-88	-99	-165	-410	-363	-404	-344	-307
Capital Expenditures (CapEx)	0.85	4.67	5.67	7.37	6.71	10	15	24	21	27	43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.51	-4.23	5.09	9.50	8.80	25	32	-7.58	-17	-57	-54
Debt-free Net Working Capital (DFNWC)	94	265	225	195	257	354	886	931	953	855	908
Net Working Capital (NWC)	94	265	225	195	257	354	886	931	953	855	350
Net Nonoperating Expense (NNE)	25	39	51	34	40	6.59	13	27	30	44	49
Net Nonoperating Obligations (NNO)	-103	-246	-124	-88	-99	-165	-410	-363	-404	-344	-307
Total Depreciation and Amortization (D&A)	1.94	3.48	5.81	7.93	10	6.28	12	13	9.09	-12	-14
Debt-free, Cash-free Net Working Capital to Revenue	-54.95%	-12.80%	6.14%	5.36%	3.55%	7.24%	6.42%	-1.42%	-3.19%	-11.20%	-8.90%
Debt-free Net Working Capital to Revenue	607.88%	801.76%	271.44%	110.11%	103.52%	100.66%	179.18%	173.99%	177.14%	167.92%	150.09%
Net Working Capital to Revenue	607.88%	801.76%	271.44%	110.11%	103.52%	100.66%	179.18%	173.99%	177.14%	167.92%	57.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.46)	($3.67)	($1.54)	($0.70)	($0.69)	($0.07)	$0.20	($0.56)	($0.88)	($1.95)	($1.56)
Adjusted Weighted Average Basic Shares Outstanding	12.49M	84.43M	87.07M	89.88M	94.99M	99.64M	100.93M	103.43M	104.66M	106.39M	107.83M
Adjusted Diluted Earnings per Share	($6.46)	($3.67)	($1.54)	($0.70)	($0.69)	($0.07)	$0.18	($0.56)	($0.88)	($1.95)	($1.56)
Adjusted Weighted Average Diluted Shares Outstanding	12.49M	84.43M	87.07M	89.88M	94.99M	99.64M	108.88M	103.43M	104.66M	106.39M	107.83M
Adjusted Basic & Diluted Earnings per Share	($6.46)	($3.67)	($1.54)	($0.70)	($0.69)	($0.07)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.49M	30.40M	85.56M	88.55M	91.83M	97.24M	102.41M	104.42M	105.46M	107.09M	109.92M
Normalized Net Operating Profit after Tax (NOPAT)	-56	-73	-81	-28	-24	-0.64	21	-31	-63	-163	-119
Normalized NOPAT Margin	-362.23%	-220.02%	-97.39%	-15.55%	-9.50%	-0.18%	4.30%	-5.80%	-11.65%	-32.00%	-19.72%
Pre Tax Income Margin	-518.40%	-323.83%	-146.54%	-27.40%	-18.52%	-2.51%	3.66%	-9.73%	-15.22%	-37.64%	-21.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-556.64	-33.00	-18.76	-4.29	-2.74	-0.12	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-389.65	-23.10	-13.13	-3.00	-1.92	-0.08	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-562.53	-34.49	-19.68	-5.09	-3.29	-1.44	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-395.54	-24.58	-14.05	-3.81	-2.47	-1.41	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from NovoCure's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.95%	-3.59%	-11.17%	-10.52%	-2.81%	4.17%	13.36%	19.28%	21.81%	20.54%
EBITDA Growth	-331.53%	-118.41%	-2,575.20%	-268.41%	-186.08%	-29.15%	28.41%	42.20%	41.46%	-18.87%
EBIT Growth	-187.78%	-83.68%	-7,375.06%	-196.57%	-136.66%	-20.33%	31.09%	46.41%	44.90%	-22.41%
NOPAT Growth	-187.78%	-83.68%	-7,375.06%	-196.57%	-136.66%	-20.33%	31.09%	46.41%	44.90%	-22.41%
Net Income Growth	-102.50%	-40.99%	-1,041.83%	-139.16%	-86.20%	-26.21%	26.95%	41.87%	38.22%	-40.02%
EPS Growth	-92.31%	-44.00%	-1,150.00%	-134.78%	-84.00%	-25.00%	28.00%	42.59%	39.13%	-35.56%
Operating Cash Flow Growth	-8.11%	-125.74%	-353.68%	-244.25%	-186.15%	-292.72%	-88.76%	92.44%	153.72%	76.29%
Free Cash Flow Firm Growth	-165.39%	-739.35%	-56.00%	-22.81%	-137.70%	6.20%	-174.82%	-45.61%	11.92%	-327.89%
Invested Capital Growth	-0.96%	-22.15%	-39.50%	-26.22%	-1.86%	-48.41%	38.99%	45.50%	32.99%	181.87%
Revenue Q/Q Growth	-7.01%	-1.96%	-4.86%	3.17%	1.01%	5.08%	3.53%	8.56%	3.15%	3.98%
EBITDA Q/Q Growth	-23.07%	-100.55%	-41.38%	-5.57%	4.43%	9.46%	21.63%	14.77%	3.21%	-83.86%
EBIT Q/Q Growth	-16.49%	-74.63%	-40.19%	-4.00%	7.05%	11.21%	19.72%	19.12%	4.43%	-97.26%
NOPAT Q/Q Growth	-16.49%	-74.63%	-40.19%	-4.00%	7.05%	11.21%	19.72%	19.12%	4.43%	-97.26%
Net Income Q/Q Growth	-10.70%	-40.36%	-42.24%	-8.21%	13.82%	4.86%	17.67%	13.89%	8.40%	-115.64%
EPS Q/Q Growth	-8.70%	-44.00%	-38.89%	-8.00%	14.81%	2.17%	20.00%	13.89%	9.68%	-117.86%
Operating Cash Flow Q/Q Growth	42.24%	-116.53%	-351.23%	-35.93%	15.05%	24.62%	-116.88%	94.55%	703.26%	-133.26%
Free Cash Flow Firm Q/Q Growth	28.95%	-16.55%	17.39%	-79.52%	-37.52%	54.00%	-142.01%	4.88%	16.82%	-123.45%
Invested Capital Q/Q Growth	-29.73%	-7.04%	8.20%	4.38%	-6.53%	-51.12%	191.47%	9.28%	-14.57%	3.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.29%	77.51%	75.76%	73.01%	74.79%	75.67%	75.68%	76.95%	77.19%	79.25%
EBITDA Margin	-16.58%	-33.92%	-50.40%	-51.58%	-48.80%	-42.05%	-31.83%	-24.99%	-23.45%	-41.47%
Operating Margin	-18.79%	-33.46%	-49.31%	-49.71%	-45.75%	-38.66%	-29.98%	-22.33%	-20.69%	-39.25%
EBIT Margin	-18.79%	-33.46%	-49.31%	-49.71%	-45.75%	-38.66%	-29.98%	-22.33%	-20.69%	-39.25%
Profit (Net Income) Margin	-20.29%	-29.05%	-43.43%	-45.55%	-38.87%	-35.19%	-27.99%	-22.20%	-19.71%	-40.88%
Tax Burden Percent	113.49%	114.57%	103.88%	106.52%	102.62%	122.18%	122.50%	146.84%	141.63%	119.41%
Interest Burden Percent	95.15%	75.76%	84.78%	86.03%	82.79%	74.51%	76.21%	67.69%	67.26%	87.21%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-179.66%	-300.17%	-341.97%	-361.42%	-412.14%	-494.84%	-232.18%	-168.77%	-185.18%	-459.41%
ROIC Less NNEP Spread (ROIC-NNEP)	-177.26%	-298.29%	-339.11%	-357.85%	-409.85%	-491.93%	-229.39%	-165.85%	-182.74%	-452.77%
Return on Net Nonoperating Assets (RNNOA)	160.86%	268.89%	297.90%	317.05%	371.60%	457.83%	201.85%	144.11%	160.85%	407.41%
Return on Equity (ROE)	-18.80%	-31.28%	-44.06%	-44.37%	-40.54%	-37.01%	-30.32%	-24.66%	-24.33%	-52.00%
Cash Return on Invested Capital (CROIC)	-122.30%	-124.39%	-148.50%	-242.65%	-398.78%	-521.40%	-348.14%	-291.35%	-274.48%	-424.95%
Operating Return on Assets (OROA)	-8.89%	-15.44%	-22.17%	-21.74%	-19.87%	-16.84%	-13.73%	-10.36%	-10.10%	-19.91%
Return on Assets (ROA)	-9.59%	-13.40%	-19.52%	-19.92%	-16.88%	-15.33%	-12.82%	-10.30%	-9.62%	-20.73%
Return on Common Equity (ROCE)	-18.80%	-31.28%	-44.06%	-44.37%	-40.54%	-37.01%	-30.32%	-24.66%	-24.33%	-52.00%
Return on Equity Simple (ROE_SIMPLE)	-18.34%	0.00%	-32.62%	-41.94%	-50.11%	0.00%	-53.64%	-46.63%	-41.52%	0.00%
Net Operating Profit after Tax (NOPAT)	-17	-30	-42	-44	-41	-36	-29	-24	-22	-44
NOPAT Margin	-13.15%	-23.43%	-34.52%	-34.80%	-32.02%	-27.06%	-20.98%	-15.63%	-14.48%	-27.48%
Net Nonoperating Expense Percent (NNEP)	-2.40%	-1.88%	-2.86%	-3.57%	-2.29%	-2.91%	-2.78%	-2.92%	-2.44%	-6.65%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.99%	-	-	-	-3.89%	-	-	-	-4.36%
Cost of Revenue to Revenue	22.71%	22.49%	24.24%	26.99%	25.21%	24.33%	24.32%	23.05%	22.81%	20.75%
SG&A Expenses to Revenue	24.82%	29.64%	34.33%	32.35%	32.90%	29.49%	28.54%	25.08%	25.86%	44.95%
R&D to Revenue	39.66%	42.69%	48.86%	43.97%	42.12%	40.59%	37.25%	36.55%	33.45%	31.76%
Operating Expenses to Revenue	96.08%	110.97%	125.07%	122.72%	120.54%	114.32%	105.65%	99.29%	97.89%	118.50%
Earnings before Interest and Taxes (EBIT)	-25	-43	-60	-63	-58	-52	-42	-34	-32	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-44	-62	-65	-62	-56	-44	-38	-36	-67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	17.87	17.45	14.68	10.60	4.37	4.40	4.65	5.10	4.69	8.95
Price to Tangible Book Value (P/TBV)	17.87	17.45	14.68	10.60	4.37	4.40	4.65	5.10	4.69	8.95
Price to Revenue (P/Rev)	14.67	14.31	12.14	8.68	3.42	3.13	3.18	3.35	2.93	5.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	191.06	198.49	149.64	97.19	35.24	66.03	24.72	25.54	26.79	54.60
Enterprise Value to Revenue (EV/Rev)	13.92	13.56	11.39	7.95	2.71	2.46	2.60	2.80	2.39	4.82
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	154.44	236.90	335.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.27	1.28	1.31	1.36	1.44	1.57	1.59	1.81	1.81	1.82
Long-Term Debt to Equity	1.27	1.28	1.31	1.36	1.44	1.57	1.59	1.81	0.27	0.27
Financial Leverage	-0.91	-0.90	-0.88	-0.89	-0.91	-0.93	-0.88	-0.87	-0.88	-0.90
Leverage Ratio	2.67	2.74	2.68	2.71	2.77	2.91	2.90	3.05	3.14	3.30
Compound Leverage Factor	2.54	2.07	2.27	2.33	2.29	2.17	2.21	2.06	2.11	2.88
Debt to Total Capital	55.90%	56.18%	56.72%	57.71%	59.06%	61.08%	61.32%	64.37%	64.46%	64.54%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	54.90%	54.96%
Long-Term Debt to Total Capital	55.90%	56.18%	56.72%	57.71%	59.06%	61.08%	61.32%	64.37%	9.57%	9.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	44.10%	43.82%	43.28%	42.29%	40.94%	38.92%	38.68%	35.63%	35.54%	35.46%
Debt to EBITDA	-9.94	-7.03	-3.92	-2.96	-2.45	-2.32	-2.50	-3.27	-3.76	-3.54
Net Debt to EBITDA	7.14	5.03	2.72	1.95	1.53	1.40	1.34	1.51	1.77	1.66
Long-Term Debt to EBITDA	-9.94	-7.03	-3.92	-2.96	-2.45	-2.32	-2.50	-3.27	-0.56	-0.53
Debt to NOPAT	-11.53	-9.02	-5.43	-4.25	-3.62	-3.49	-3.80	-5.04	-5.88	-5.49
Net Debt to NOPAT	8.29	6.45	3.76	2.81	2.26	2.11	2.03	2.33	2.78	2.57
Long-Term Debt to NOPAT	-11.53	-9.02	-5.43	-4.25	-3.62	-3.49	-3.80	-5.04	-0.87	-0.82
Altman Z-Score	7.04	6.53	5.37	3.69	1.43	1.21	1.28	1.36	0.67	1.55
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.81	7.00	7.32	7.10	6.67	5.78	6.26	6.46	1.49	1.46
Quick Ratio	7.50	6.65	6.94	6.74	6.28	5.43	5.84	6.00	1.40	1.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-20	-16	-29	-40	-18	-45	-42	-35	-79
Operating Cash Flow to CapEx	393.13%	-57.64%	-274.75%	-328.05%	-266.29%	-213.43%	-267.94%	-15.03%	97.13%	-38.59%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.46	0.45	0.44	0.43	0.44	0.46	0.46	0.49	0.51
Accounts Receivable Turnover	5.97	5.98	5.94	6.02	6.60	6.91	7.51	8.11	8.74	8.94
Inventory Turnover	4.68	4.27	3.84	3.91	3.92	3.80	3.57	3.62	3.59	3.75
Fixed Asset Turnover	26.19	19.43	16.98	14.99	13.38	12.10	11.02	10.22	9.73	9.37
Accounts Payable Turnover	1.69	1.46	1.55	1.51	1.59	1.43	1.60	1.54	1.59	1.38
Days Sales Outstanding (DSO)	61.10	61.02	61.41	60.59	55.29	52.84	48.58	45.03	41.76	40.84
Days Inventory Outstanding (DIO)	78.00	85.48	95.05	93.37	93.14	96.07	102.19	100.81	101.65	97.43
Days Payable Outstanding (DPO)	216.21	250.71	235.49	242.47	229.49	255.49	228.60	237.00	228.99	265.38
Cash Conversion Cycle (CCC)	-77.11	-104.21	-79.04	-88.51	-81.05	-106.58	-77.82	-91.16	-85.58	-127.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	40	37	40	42	39	19	55	60	52	53
Invested Capital Turnover	13.66	12.81	9.91	10.39	12.87	18.29	11.06	10.80	12.78	16.72
Increase / (Decrease) in Invested Capital	-0.39	-10	-26	-15	-0.74	-18	16	19	13	34
Enterprise Value (EV)	7,552	7,294	5,950	4,034	1,367	1,252	1,366	1,542	1,382	2,918
Market Capitalization	7,958	7,698	6,342	4,408	1,722	1,595	1,670	1,843	1,691	3,224
Book Value per Share	$4.25	$4.20	$4.10	$3.91	$3.69	$3.39	$3.35	$3.36	$3.33	$3.33
Tangible Book Value per Share	$4.25	$4.20	$4.10	$3.91	$3.69	$3.39	$3.35	$3.36	$3.33	$3.33
Total Capital	1,010	1,007	998	983	962	931	929	1,015	1,015	1,016
Total Debt	565	566	566	567	568	569	570	653	654	655
Total Long-Term Debt	565	566	566	567	568	569	570	653	97	97
Net Debt	-406	-404	-392	-374	-355	-344	-304	-301	-309	-307
Capital Expenditures (CapEx)	5.70	6.43	6.09	6.93	7.25	6.82	12	11	11	8.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.25	-17	-18	-26	-32	-57	-31	-31	-46	-54
Debt-free Net Working Capital (DFNWC)	961	953	940	915	891	855	842	924	918	908
Net Working Capital (NWC)	961	953	940	915	891	855	842	924	360	350
Net Nonoperating Expense (NNE)	9.35	7.22	11	14	8.71	11	9.70	9.87	8.11	22
Net Nonoperating Obligations (NNO)	-406	-404	-392	-374	-355	-344	-304	-301	-309	-307
Total Depreciation and Amortization (D&A)	2.89	-0.58	-1.33	-2.35	-3.89	-4.54	-2.57	-4.00	-4.28	-3.57
Debt-free, Cash-free Net Working Capital to Revenue	-1.71%	-3.19%	-3.54%	-5.11%	-6.36%	-11.20%	-5.95%	-5.67%	-7.98%	-8.90%
Debt-free Net Working Capital to Revenue	177.16%	177.14%	179.95%	180.32%	176.76%	167.92%	160.27%	167.95%	158.83%	150.09%
Net Working Capital to Revenue	177.16%	177.14%	179.95%	180.32%	176.76%	167.92%	160.27%	167.95%	62.36%	57.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.25)	($0.36)	($0.50)	($0.54)	($0.46)	($0.45)	($0.36)	($0.31)	($0.28)	($0.61)
Adjusted Weighted Average Basic Shares Outstanding	104.88M	104.66M	105.67M	106.29M	106.77M	106.39M	107.27M	107.70M	108.25M	107.83M
Adjusted Diluted Earnings per Share	($0.25)	($0.36)	($0.50)	($0.54)	($0.46)	($0.45)	($0.36)	($0.31)	($0.28)	($0.61)
Adjusted Weighted Average Diluted Shares Outstanding	104.88M	104.66M	105.67M	106.29M	106.77M	106.39M	107.27M	107.70M	108.25M	107.83M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	104.95M	105.46M	106.21M	106.62M	106.86M	107.09M	107.61M	108.22M	108.20M	109.92M
Normalized Net Operating Profit after Tax (NOPAT)	-17	-30	-42	-44	-41	-36	-29	-24	-22	-44
Normalized NOPAT Margin	-13.15%	-23.43%	-34.52%	-34.80%	-32.02%	-27.06%	-20.98%	-15.63%	-14.48%	-27.48%
Pre Tax Income Margin	-17.88%	-25.35%	-41.81%	-42.76%	-37.87%	-28.80%	-22.85%	-15.12%	-13.92%	-34.23%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About NovoCure's Financials

When does NovoCure's financial year end?

According to the most recent income statement we have on file, NovoCure's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NovoCure's net income changed over the last 10 years?

NovoCure's net income appears to be on an upward trend, with a most recent value of -$168.63 million in 2024, rising from -$80.68 million in 2014. The previous period was -$207.04 million in 2023.

What is NovoCure's operating income?

NovoCure's total operating income in 2024 was -$170.50 million, based on the following breakdown:

Total Gross Profit: $468.04 million
Total Operating Expenses: $638.54 million

How has NovoCure revenue changed over the last 10 years?

Over the last 10 years, NovoCure's total revenue changed from $15.49 million in 2014 to $605.22 million in 2024, a change of 3,807.2%.

How much debt does NovoCure have?

NovoCure's total liabilities were at $880.61 million at the end of 2024, a 12.4% increase from 2023, and a 4,302.8% increase since 2014.

How much cash does NovoCure have?

In the past 10 years, NovoCure's cash and equivalents has ranged from $57.61 million in 2014 to $240.82 million in 2023, and is currently $163.77 million as of their latest financial filing in 2024.

How has NovoCure's book value per share changed over the last 10 years?

Over the last 10 years, NovoCure's book value per share changed from 7.84 in 2014 to 3.33 in 2024, a change of -57.5%.

Remove Ads

Related Companies

This page (NASDAQ:NVCR) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Financials

Frequently Asked Questions About NovoCure's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NovoCure (NVCR) Financials

Annual Income Statements for NovoCure

Quarterly Income Statements for NovoCure

Annual Cash Flow Statements for NovoCure

Quarterly Cash Flow Statements for NovoCure

Annual Balance Sheets for NovoCure

Quarterly Balance Sheets for NovoCure

Annual Metrics and Ratios for NovoCure

Quarterly Metrics and Ratios for NovoCure

Frequently Asked Questions About NovoCure's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools